NCT06517875 - Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

October 14, 2026

Study Completion Date

November 13, 2026

Conditions

Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

Interventions

DRUG

Momelotinib

Momelotinib will be administered orally.

DRUG

Luspatercept

Luspatercept will be administered subcutaneously.

Trial Locations (12)

161

RECRUITING

GSK Investigational Site, Roma

29010

RECRUITING

GSK Investigational Site, Málaga

29609

RECRUITING

GSK Investigational Site, Brest

30029

RECRUITING

GSK Investigational Site, Nîmes

37203

RECRUITING

GSK Investigational Site, Nashville

46026

RECRUITING

GSK Investigational Site, Valencia

49933

RECRUITING

GSK Investigational Site, Angers

69004

RECRUITING

GSK Investigational Site, Lyon

75010

RECRUITING

GSK Investigational Site, Paris

86021

RECRUITING

GSK Investigational Site, Poitiers

M5G 2M9

RECRUITING

GSK Investigational Site, Toronto

06202

RECRUITING

GSK Investigational Site, Nice